Key Points
- United Therapeutics EVP Paul Mahon sold 8,300 shares on June 4 at an average price of $547.07, generating about $4.54 million in proceeds. After the sale, he still held 45,172 shares, representing a 15.52% reduction in his ownership stake.
- The stock was slightly lower, opening at $547.69 and down 0.3% on the day. United Therapeutics has a market cap of $23.25 billion and has traded between $272.12 and $609.35 over the past year.
- Recent earnings missed expectations, with Q1 EPS of $5.82 versus analysts’ estimate of $7.00 and revenue of $781.5 million versus $797.4 million expected. Despite that miss, analysts remain generally constructive, with a consensus rating of “Moderate Buy” and an average price target of $619.42.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the firm's stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $547.07, for a total value of $4,540,681.00. Following the transaction, the executive vice president directly owned 45,172 shares in the company, valued at $24,712,246.04. This trade represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
United Therapeutics Stock Down 0.3%
Shares of United Therapeutics stock opened at $547.69 on Friday. The firm has a market cap of $23.25 billion, a PE ratio of 20.22, a price-to-earnings-growth ratio of 1.78 and a beta of 0.57. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The company's fifty day simple moving average is $568.06 and its two-hundred day simple moving average is $518.61.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics's revenue was down 1.6% on a year-over-year basis. During the same period last year, the business earned $6.63 EPS. As a group, sell-side analysts expect that United Therapeutics Corporation will post 26.92 earnings per share for the current fiscal year.
Institutional Trading of United Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. Optimize Financial Inc purchased a new stake in United Therapeutics in the third quarter worth about $444,000. Leuthold Group LLC boosted its position in shares of United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company's stock worth $5,200,000 after purchasing an additional 3,126 shares in the last quarter. Tobam boosted its position in shares of United Therapeutics by 183.9% in the 3rd quarter. Tobam now owns 7,646 shares of the biotechnology company's stock worth $3,205,000 after purchasing an additional 4,953 shares in the last quarter. UBS Group AG boosted its position in shares of United Therapeutics by 45.3% in the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company's stock worth $110,045,000 after purchasing an additional 70,445 shares in the last quarter. Finally, Perpetual Ltd bought a new stake in shares of United Therapeutics in the 4th quarter worth approximately $1,059,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several analysts recently issued reports on UTHR shares. Oppenheimer raised their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday, February 26th. Cantor Fitzgerald raised their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a research note on Thursday, March 12th. Bank of America raised their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 31st. HC Wainwright raised their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a research note on Tuesday, March 31st. Finally, UBS Group raised their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a "buy" rating in a research note on Thursday, March 5th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $619.42.
Read Our Latest Report on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
